Drug Profile
Research programme: Alzheimer's disease therapeutics - Socratech LLC
Alternative Names: M007-LRPIVLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Socratech
- Class Small molecules
- Mechanism of Action Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA
- 21 Oct 2009 Preclinical pharmacodynamics data presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
- 22 Nov 2007 Preclinical trials in Alzheimer's disease in USA (unspecified route)